BPC-157: 30 years of animal research, what it tells us
A peptide first identified in stomach juice has stacked up rodent studies for decades — but human data is a different story.
TL;DR
- BPC-157 has roughly 30 years of preclinical animal research, mostly in rodents.
- The animal evidence consistently describes effects on tendon, gut, and soft-tissue repair.
- Large human clinical trials are limited. As of September 2026, FDA's final decision on adding BPC-157 to the Section 503A bulks list is pending.
What it is
BPC-157 (in plain English: "body protection compound 157," a 15-amino-acid peptide derived from a protective protein found in human gastric juice) was first described in research literature in the 1990s by a group at the University of Zagreb. The peptide drew attention for its consistent effects in rodent models of tissue and gut injury (Sikiric et al., Current Pharmaceutical Design, 2018). As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
How it works
Think of the body's repair system like a road crew. Most days the crew handles potholes at a steady pace. After a bad storm — an injury, an inflamed gut — the crew needs more workers and more direction. The animal research describes BPC-157 as something that helps coordinate that response: more blood vessel formation around damaged tissue (in plain English: angiogenesis), better organization of repair cells, and faster closure of injured tendon and gut tissue in rodent models. The mechanism described in the literature is signaling — not a magic ingredient — and the bulk of the evidence is preclinical.
Who asks about it
People come to this question after seeing BPC-157 cited in podcasts, on social platforms, or in older clinic protocols and want to know whether the research supports the marketing. The honest answer: the animal literature is real and reproducible. Human trials have not caught up. And the regulatory status changed in 2024–2026 in ways that affect access.
What the research says
A 2018 review summarized BPC-157 as having a "remarkable healing effect" across multiple rodent injury models, while explicitly noting the absence of large human trials (Sikiric et al., Current Pharmaceutical Design, 2018). Other reviews describe consistent effects on tendon and ligament healing in rats and mice (Chang et al., Journal of Applied Physiology, 2011). The "30 years of research" framing is accurate — most of those 30 years are animal data.
What to know before considering it
Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. Any compounded peptide therapy requires a licensed physician evaluation.
The Halftime POV
A long animal-research history is a real signal — and it is also not the same as a human-trial conclusion. The honest BPC-157 read is: real preclinical depth, real human-data gaps, and current regulatory pause. All three things stay true at the same time.
Related reading:
- BPC-157 and the Category 2 question
- BPC-157 human trials: what has actually been studied
- Category 1 vs Category 2 peptides: the access framework
FAQ
Q: What does the BPC-157 research actually show? A: Most of the published BPC-157 evidence is from rodent studies of tissue, tendon, and gut healing. The animal data is consistent and reproducible; large human trials are limited.
Q: Are there human studies of BPC-157? A: Very few. Most published BPC-157 research is preclinical. The peptide is sometimes referenced in compounding contexts but does not have a body of large human clinical trials.
Q: Is BPC-157 currently legal? A: FDA placed BPC-157 in Category 2 in 2023. FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, BPC-157 is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Disclaimer
As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Sikiric P et al., Current Pharmaceutical Design, 2018 — BPC-157: A Review of Its Pharmacology and Healing Effects
- Chang CH et al., Journal of Applied Physiology, 2011 — The Promoting Effect of BPC-157 on Tendon Healing
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What does the BPC-157 research actually show?
Most of the published BPC-157 evidence is from rodent studies of tissue, tendon, and gut healing. The animal data is consistent and reproducible; large human trials are limited.
Are there human studies of BPC-157?
Very few. Most published BPC-157 research is preclinical. The peptide is sometimes referenced in compounding contexts but does not have a body of large human clinical trials.
Is BPC-157 currently legal?
FDA placed BPC-157 in Category 2 in 2023. FDA removed BPC-157 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, BPC-157 is not in any FDA 503A category and is not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. As of September 2026, FDA has not made a final decision on BPC-157. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding BPC-157 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
Keep reading
For living longer, and still feeling like yourself. It starts with your labs.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.